CDK9 and cancer: Our results identify a physiologically actionable therapeutic window at which CDK9 inhibition is effective, thereby supporting the utility and predictive value of this time- and cost-effective platform to reveal previously inaccessible information (such as on-target reversible toxicities) relevant to the clinical development of candidate cancer targets.